Cargando…

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients

Detalles Bibliográficos
Autores principales:	Guarino, Maria, Esposito, Ilaria, Portella, Giuseppe, Cossiga, Valentina, Loperto, Ilaria, Pignata, Luca, Tortora, Raffaella, Attanasio, Maria Rosaria, Cennamo, Michele, Capasso, Mario, Terracciano, Daniela, Cutolo, Francesco Maria, Lanza, Alfonso Galeota, Lieto, Raffaele, di Somma, Sarah, Picciotto, Francesco Paolo, Morisco, Filomena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Saturday 25 June: Liver transplantation and hepatobiliary surgery: Clinical aspects
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252389/ http://dx.doi.org/10.1016/S0168-8278(22)01855-4

Ejemplares similares

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

COVID-19 and Fatty Liver Disorders
por: Guarino, Maria, et al.
Publicado: (2023)

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients
por: Herrán, Aitor Odriozola, et al.
Publicado: (2022)

Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients
por: Mendizabal, Manuel, et al.
Publicado: (2022)

Does m-RNA vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients?
por: Comandini, Ubaldo Visco, et al.
Publicado: (2022)

Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap?
por: Montalbano, Marzia, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2022)

The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation
por: Cooper, Katherine, et al.
Publicado: (2022)

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2022)

Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications
por: Singal, Ashwani, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients
por: Calleri, Alberto, et al.
Publicado: (2022)

SARS-CoV-2 infection in liver transplant recipients-a single center case series from Romania
por: Husar-Sburlan, Ioana-Alexandra, et al.
Publicado: (2022)

Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients
por: Kounis, Ilias, et al.
Publicado: (2022)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up
por: Kirchner, Theresa, et al.
Publicado: (2022)

Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome
por: Cohen-Naftaly, Michal, et al.
Publicado: (2022)

COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study
por: Guarino, Maria, et al.
Publicado: (2022)

Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.
por: Sempere, Elena Diago, et al.
Publicado: (2022)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

P203 Earlier identification of human immunodeficiency virus and hepatitis C virus in high-risk emergency departments
por: Fenton, J., et al.
Publicado: (2009)

Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
por: Cossiga, Valentina, et al.
Publicado: (2023)

AF.93 COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIAN CASE-CONTROL DOUBLE-CENTER STUDY
por: Guarino, M., et al.
Publicado: (2021)

SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19
por: Lasagni, Alberto, et al.
Publicado: (2022)

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
por: Guarino, Maria, et al.
Publicado: (2022)

Liver and spleen volumes are associated with prognosis of compensated and decompensated cirrhosis and parallel its natural history
por: Romero‐Cristóbal, Mario, et al.
Publicado: (2022)

Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression
por: Jacobs, Angus, et al.
Publicado: (2022)

Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy
por: Mangia, Alessandra, et al.
Publicado: (2021)

High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort
por: Llop, Elba, et al.
Publicado: (2021)

Inhibition of NAE‐dependent protein hyper‐NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease
por: Lee‐Law, Pui Y., et al.
Publicado: (2021)

Toward a more precise prognostic stratification in acute decompensation of cirrhosis: The Padua model 2.0
por: Zanetto, Alberto, et al.
Publicado: (2023)

COVID‐19 mortality in cirrhosis is determined by cirrhosis‐associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry
por: Brozat, Jonathan F., et al.
Publicado: (2022)

Invalidity of Tokyo guidelines in acute biliary pancreatitis: A multicenter cohort analysis of 944 pancreatitis cases
por: Juhász, Márk Félix, et al.
Publicado: (2023)

Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs
por: Díaz‐González, Álvaro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bv8uqu40ug0dn3eg9ek5ou4m4m